Please login to the form below

Not currently logged in
Email:
Password:

KRAS

This page shows the latest KRAS news and features for those working in and with pharma, biotech and healthcare.

Amgen aims for first KRAS inhibitor approval in the US

Amgen aims for first KRAS inhibitor approval in the US

If approved, it would become the first therapy designed to target the KRAS pathway, an oncogene that is implicated in around a third of all human cancers. ... In NSCLC, KRAS G12C is the most common KRAS mutation, with around 13% of patients with NSCLC in

Latest news

More from news
Approximately 6 fully matching, plus 25 partially matching documents found.

Latest Intelligence

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    The questions being asked are, what does an individual’s mutational profile look like, and do we have a drug to treat it; ie, do they have EGFR mutations, KRAS or

  • Interview: AstraZeneca's Susan Galbraith Interview: AstraZeneca's Susan Galbraith

    This includes people with NSCLC who have a mutated KRAS gene - an area where no specific treatment option exists. ... With selumetinib you've now got that plus another 20-25 per cent of NSCLC cases - people with the KRAS mutation.”.

  • Pharma deals during September 2012 Pharma deals during September 2012

    advanced KRAS; a wild-type metastatic colorectal cancer (mCRC). ... 665. Symphogen / Merck KGaA. Product licence. Sym004 for advanced KRAS; a wild-type metastatic colorectal cancer (mCRC) (phase I /II).

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Graphite Digital

We’re a digital CX agency collaborating with healthcare and pharmaceutical organisations to help them connect more deeply with their audiences...

Latest intelligence

Diversity in clinical trials: looking back at our 2021 blogs
In this blog, we look back at the Innovative Trials' Equality & Diversity (E&D) committee blogs across 2021...
What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...